BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29857045)

  • 1. Rapid Bioavailability and Disposition protocol: A novel higher throughput approach to assess pharmacokinetics and steady-state brain distribution with reduced animal usage.
    Fu T; Gao R; Scott-Stevens P; Chen Y; Zhang C; Wang J; Summerfield S; Liu H; Sahi J
    Eur J Pharm Sci; 2018 Sep; 122():13-21. PubMed ID: 29857045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Intravenous Infusion Study Design to Simultaneously Determine Brain Penetration and Systemic Pharmacokinetic Parameters in Rats.
    Noh K; Pietrasiewicz A; Liu X; Wei C
    Drug Metab Dispos; 2021 Feb; 49(2):142-151. PubMed ID: 33262223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain penetration assessment in vivo: a reliable and simple method in anesthetized rats at steady state.
    Andersen CA; Perfetti P; Nibbio M; Bellini M; Angelini R; Fornasier M
    J Neurosci Methods; 2014 Jul; 232():199-206. PubMed ID: 24880048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition, oral bioavailability, and tissue distribution of zearalenone in rats at various dose levels.
    Shin BS; Hong SH; Bulitta JB; Hwang SW; Kim HJ; Lee JB; Yang SD; Kim JE; Yoon HS; Kim DJ; Yoo SD
    J Toxicol Environ Health A; 2009; 72(21-22):1406-11. PubMed ID: 20077212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
    Sato S; Matsumiya K; Tohyama K; Kosugi Y
    AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cassette dosing for pharmacokinetic screening in drug discovery: comparison of clearance, volume of distribution, half-life, mean residence time, and oral bioavailability obtained by cassette and discrete dosing in rats.
    Nagilla R; Nord M; McAtee JJ; Jolivette LJ
    J Pharm Sci; 2011 Sep; 100(9):3862-74. PubMed ID: 21360708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing extent of brain penetration in vivo (K
    Langthaler K; Jones CR; Brodin B; Bundgaard C
    Eur J Pharm Sci; 2023 Nov; 190():106554. PubMed ID: 37543065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid in vivo oral screening in rats: reliability, acceptance criteria, and filtering efficiency.
    Mei H; Korfmacher W; Morrison R
    AAPS J; 2006 Jul; 8(3):E493-500. PubMed ID: 17025267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
    Zhang T; Heimbach T; Lin W; Zhang J; He H
    J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of the novel antifolate pemetrexed to the brain.
    Dai H; Chen Y; Elmquist WF
    J Pharmacol Exp Ther; 2005 Oct; 315(1):222-9. PubMed ID: 15987831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of pharmacokinetics and brain penetration data of adult zebrafish with higher mammals including humans.
    Kulkarni P; Medishetti R; Nune N; Yellanki S; Sripuram V; Rao P; Sriram D; Saxena U; Oruganti S; Yogeeswari P
    J Pharmacol Toxicol Methods; 2017; 88(Pt 2):147-152. PubMed ID: 28974368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender effect on the pharmacokinetics of thymoquinone: Preclinical investigation and
    Ahmad A; Alqahtani S; Jan BL; Raish M; Rabba AK; Alkharfy KM
    Saudi Pharm J; 2020 Apr; 28(4):403-408. PubMed ID: 32273798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of In Vivo Pharmacokinetic Parameters and Time-Exposure Curves in Rats Using Machine Learning from the Chemical Structure.
    Obrezanova O; Martinsson A; Whitehead T; Mahmoud S; Bender A; Miljković F; Grabowski P; Irwin B; Oprisiu I; Conduit G; Segall M; Smith GF; Williamson B; Winiwarter S; Greene N
    Mol Pharm; 2022 May; 19(5):1488-1504. PubMed ID: 35412314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species.
    Daublain P; Feng KI; Altman MD; Martin I; Mukherjee S; Nofsinger R; Northrup AB; Tschirret-Guth R; Cartwright M; McGregor C
    Mol Pharm; 2017 May; 14(5):1634-1645. PubMed ID: 28329443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.